New York State Teachers Retirement System Sells 23,805 Shares of Elanco Animal Health Incorporated $ELAN

New York State Teachers Retirement System lessened its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 8.2% in the 1st quarter, Holdings Channel reports. The firm owned 267,250 shares of the company’s stock after selling 23,805 shares during the period. New York State Teachers Retirement System’s holdings in Elanco Animal Health were worth $6,395,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Parallel Advisors LLC grew its holdings in shares of Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after buying an additional 392 shares during the period. Lazard Asset Management LLC raised its stake in Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after buying an additional 425 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its holdings in Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares in the last quarter. Meeder Advisory Services Inc. lifted its holdings in Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after acquiring an additional 510 shares in the last quarter. Finally, Fifth Third Wealth Advisors LLC grew its stake in Elanco Animal Health by 4.2% in the first quarter. Fifth Third Wealth Advisors LLC now owns 14,273 shares of the company’s stock valued at $342,000 after acquiring an additional 579 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 4,971 shares of Elanco Animal Health stock in a transaction that occurred on Friday, May 15th. The stock was acquired at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the acquisition, the chief executive officer owned 171,971 shares of the company’s stock, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Rajeev A. Modi acquired 4,911 shares of the company’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings cut Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. UBS Group reiterated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Finally, Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $28.55.

Elanco Animal Health Price Performance

NYSE:ELAN opened at $24.64 on Wednesday. The stock has a market capitalization of $12.31 billion, a PE ratio of -49.28, a P/E/G ratio of 1.64 and a beta of 1.68. Elanco Animal Health Incorporated has a 1-year low of $13.39 and a 1-year high of $27.72. The firm has a fifty day simple moving average of $23.29 and a 200 day simple moving average of $23.73. The company has a current ratio of 2.16, a quick ratio of 1.12 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.28 billion. During the same quarter last year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts expect that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.